Randomised population (n = 3,036)

Lumiracoxib 100 mg o.d. (n = 757)
- Did not receive study drug (n = 2)
- ITT/safety population (n = 755)
  - Discontinuations (n = 402; 53.1%)
    - Administrative problems n = 102 (13.5%)
    - Due to protocol amendment† n = 90 (11.9%)
    - Unsatisfactory therapeutic effect n = 97 (12.8%)
    - Adverse events n = 96 (12.7%)
    - Withdrew consent n = 78 (10.3%)
    - Due to adverse publicity† n = 25 (3.3%)
    - Protocol violation n = 10 (1.3%)
    - Lost to follow-up n = 9 (1.2%)
  - Abnormal laboratory value or test result n = 8 (1.1%)
  - Completed (n = 355; 46.9%)

Lumiracoxib 100 mg b.i.d. (n =1,520)
- Did not receive study drug (n = 1)
- ITT/safety population (n = 1519)
  - Discontinuations (n = 792; 52.1%)
    - Administrative problems n = 226 (14.9%)
    - Due to protocol amendment† n = 199 (13.1%)
    - Unsatisfactory therapeutic effect n = 158 (10.4%)
    - Adverse events n = 187 (12.3%)
    - Withdrew consent n = 170 (11.2%)
    - Due to adverse publicity† n = 68 (4.5%)
    - Protocol violation n = 22 (1.4%)
    - Lost to follow-up n = 7 (0.5%)
  - Abnormal laboratory value or test result n = 16 (1.1%)
  - No longer required treatment n = 3 (0.2%)
  - Completed (n = 728; 47.9%)

Celecoxib 200 mg o.d. (n = 759)
- Did not receive study drug (n = 1)
- ITT/safety population (n = 758)
  - Discontinuations (n = 415; 54.7%)
    - Administrative problems n = 119 (15.7%)
    - Due to protocol amendment† n = 103 (13.6%)
    - Unsatisfactory therapeutic effect n = 88 (11.6%)
    - Adverse events n = 89 (11.7%)
    - Withdrew consent n = 93 (12.3%)
    - Due to adverse publicity† n = 27 (3.6%)
    - Protocol violation n = 10 (1.3%)
    - Lost to follow-up n = 8 (1.1%)
  - Abnormal laboratory value or test result n = 16 (1.1%)
  - No longer required treatment n = 2 (0.3%)
  - Completed (n = 344; 45.3%)